Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Coronary Intravascular Lithotripsy (IVL): Clinical Performance and Safety
Coronary intravascular lithotripsy (IVL) is an established plaque-modification technique designed to facilitate optimal stent expansion in moderately to severely calcified coronary lesions. By delivering localized acoustic pressure waves through a low-pressure balloon system, IVL induces controlled microfractures in both superficial and deep calcium, improving vessel compliance while minimizing vascular trauma.
Clinical evidence from the Disrupt CAD I–IV trials demonstrates a procedural success rate of approximately 92%, defined by successful stent delivery with residual stenosis below target thresholds and absence of in-hospital major adverse cardiac events. In these studies, residual stenosis <50% was achieved in approximately 95% of treated lesions, reflecting effective calcium modification and favorable acute luminal gain.
Importantly, IVL is associated with a low incidence of serious complications, including a coronary perforation rate below 1%, which is substantially lower than that reported with some atherectomy-based strategies. This safety profile, combined with technical simplicity and a short learning curve, supports IVL as a valuable option for contemporary percutaneous coronary intervention in calcified coronary artery disease.”
Title: Shocking the Rock With Coronary Intravascular Lithotripsy in Contemporary Practice
Authors: Debabrata Dash, Anna Emily Bortnic
Read the Full Article on American College of Cardiology

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series